Opthea Limited (NASDAQ:OPT – Get Free Report) traded up 1.7% on Friday . The stock traded as high as $4.18 and last traded at $4.11. 30,069 shares traded hands during mid-day trading, an increase of 24% from the average session volume of 24,241 shares. The stock had previously closed at $4.04.
Wall Street Analyst Weigh In
Separately, HC Wainwright dropped their target price on Opthea from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.
Check Out Our Latest Research Report on OPT
Opthea Stock Up 1.7 %
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
- Five stocks we like better than Opthea
- How to invest in marijuana stocks in 7 steps
- California Resources Stock Could Be a Huge Long-Term Winner
- Best Stocks Under $10.00
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
